| Literature DB >> 30895242 |
Luis Bahamondes1, Claudio Villarroel2, Natalia Frías Guzmán3, Silvia Oizerovich4, Norma Velázquez-Ramírez5, Ilza Monteiro1.
Abstract
STUDY QUESTION: Can the high rate and associated burden of unintended pregnancy (UP) and adolescent pregnancy in Latin America and the Caribbean (LAC) be reduced through wider access to and use of long-acting reversible contraceptive (LARC) methods? SUMMARY ANSWER: Studies show that impoved access to and use of LARC methods is an effective tool for reducing the high rates of UP, unsafe abortion and abortion-related complications, and maternal deaths (as well as reducing their social and financial burden), and we have provided recommendations to help achieve this in LAC. WHAT IS KNOWN ALREADY: LAC comprises 46 countries with 650 million inhabitants, and shows large disparities in socioeconomic development, access to health services and attention to sexual and reproductive health rights. The exercise of these rights and universal access to sexual and reproductive health (SRH) programmes is a key strategy for improving maternal health by reducing the number of UPs, the rate of women's and child mortality and morbidity, and the number of unsafe abortions. The implementation of SRH programmes in the region has contributed to a decrease in pregnancy rates of more than 50% over 40 years. However, despite this progress, the numbers of UP and adolescent pregnancies are still among the highest worldwide, which can be attributed in large part to the low prevalence of use of LARC methods. STUDY DESIGN SIZE DURATION: This is a position paper with the objective of reviewing the magnitude and burden of UP in LAC, as well as available LARC methods and barriers to their access, with the goal of increasing knowledge and awareness among healthcare professionals (HCP), policymakers and the general public about the potential to reduce UP rates through the increased use of LARC. PARTICIPANTS/MATERIALS SETTINGEntities:
Keywords: Caribbean; Latin America; adolescents; burden of unplanned pregnancy; contraception; fertility rate; long-acting reversible contraceptives; maternal mortality; unplanned pregnancy; unsafe abortion
Year: 2018 PMID: 30895242 PMCID: PMC6276683 DOI: 10.1093/hropen/hox030
Source DB: PubMed Journal: Hum Reprod Open ISSN: 2399-3529
Figure 1Adolescent birth rate by region, in 1990–1995 and 2010–2015 (adapted from World Fertility Patterns 2015—United Nations, 2015c).
Figure 2Contraceptive prevalence by method among sexually active women in Latin America and the Caribbean who are married or in union. LAC, Latin America and the Caribbean; LARCs, Long-Acting Reversible Contraceptive methods; Pill, oral contraceptive pill.
Common myths affecting the use of long-acting reversible contraceptives methods in Latin America and the Caribbean.
| Stakeholders | Myth | Evidence |
|---|---|---|
| Policymakers | LARC methods are more costly than other modern methods of contraception | LARC methods are highly cost-effective in the long term as a result of their high efficacy ( |
| HCP | There are many requirements for IUC or implant placement | The commons requirements prior to placing an IUC is to have a gynaecologic exam and that the HCP be reasonably sure a woman is not currently pregnant ( |
| LARC methods have low efficacy | LARC methods are top-tier contraceptives based on both efficacy and effectiveness, with pregnancy rates of less than 1 per 100 woman-years for both perfect and typical use ( | |
| Perforation risk is perceived to be greater in nulligravidas | No data show a difference in perforation risk between nulligravida and parous women ( | |
| Adolescents and young adults do not like to use LARC methods | Given the availability of no-cost contraception, ~75% of women (including adolescents) chose LARC, and continuation was significantly higher among LARC- than non-LARC users ( | |
| Given their age, adolescents cannot decide for themselves an appropriate contraceptive method | The Convention on the Rights of the Child indicates the right to the highest level of health and access to medical services, with an emphasis on those related to primary healthcare ( | |
| Individuals with disabilities do not require contraceptive counselling | Prejudices associated with the sexuality and reproduction of the disabled have no bearing on their right to receive contraceptive counselling and methods ( | |
| Use of LARC causes osteoporosis | No significant decrease in bone mineral density has been shown following use of LARC ( | |
| General Public (including users, partners, relatives and general community) | The pain associated with IUC placement is enough to serve as a deterrent | The available studies used a scale of 0 (no pain) to 10 (severe pain) and showed that the majority of women rated IUC placement as 2 or less, and only 4% rated it ≥7 ( |
| IUCs will not fit in the uterus of nulligravidas | WHO does not restrict use of IUCs on the basis of age or parity. Both parous and nulligravidas have an IUC expulsion rate of less than 5% ( | |
| Implants and IUCs cause cancer | Neither implants nor IUCs have shown a causal relationship with gynaecologic or other cancers. Indeed, some IUCs have shown a potential protective effect against both endometrial and cervical cáncer ( | |
| The government encourages contraceptive use to limit minority populations | No evidence. However, HCPs must consider how women’s experiences may influence their responses to contraceptive counselling, particularly with regard to race and income ( | |
| Both HCPs and General Public | IUC use causes abortions | LARCs act prior to fertilization or by changing cervical mucus ( |
| IUC use carries a higher risk of developing PID and later infertility | After the first 20 days of placement, risk of PID is the same in both LARC users and nonusers. There is no change in fertility rates following removal of LARC ( | |
| IUCs can only be placed during menstrual periods | An IUC can be safely placed at any time during the menstrual cycle ( |
LARC, long-acting reversible contraceptive; HCP, healthcare professionals; IUC, intrauterine contraceptive; PID, pelvic inflammatory disease; WHO, the World Health Organization.